Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA3 | P07451 | 1/20 | 0.52 |
| ▸ | CA4 | P22748 | 1/20 | 0.52 |
| ▸ | CA6 | P23280 | 1/20 | 0.52 |
| ▸ | CA5A | P35218 | 1/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.52 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.52 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.41 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.41 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.40 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2852817 | 1.00 | CA1 (0.52) | CA1CA2CA12CA3CA4 | |
| SCHEMBL13513315 | 0.92 | CA1 (0.51) | CA1CA2CA12CA3CA4 | |
| SCHEMBL2851625 | 0.89 | CA12 (0.41) | CA1CA2CA12CA3CA4 | |
| SCHEMBL2862880 | 0.86 | CA1 (0.59) | CA1CA2CA12CA3CA4 | |
| SCHEMBL2858060 | 0.86 | CA1 (0.59) | CA1CA2CA12CA3CA4 | |
| SCHEMBL12799325 | 0.85 | CTSS (0.47) | CA1CA2 | |
| SCHEMBL2854932 | 0.85 | CA1 (0.57) | CA1CA2CA12CA3CA4 | |
| SCHEMBL2849775 | 0.85 | CA12 (0.57) | CA1CA2CA12CA3CA4 | |
| SCHEMBL2856891 | 0.84 | CA1 (0.59) | CA1CA2CA12CA3CA4 | |
| SCHEMBL2857336 | 0.84 | CA12 (0.56) | CA1CA2CA12CA3CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902401-B2 | Fluorinated compounds | NPS PHARMACEUTICALS, INC. (US) | 2011-03-08 | — | — | US | claimed |
| EP-1963277-B1 | FLUORINATED COMPOUNDS | NPS PHARMA INC (US) | 2010-01-20 | — | — | EP | claimed |
| US-20090005433-A1 | Fluorinated Compounds | NPS PHARMACEUTICALS, INC. | 2009-01-01 | — | — | US | claimed |
| EP-1963277-A1 | FLUORINATED COMPOUNDS | NPS PHARMACEUTICALS, INC. (US) | 2008-09-03 | — | — | EP | claimed |
| WO-2007076306-A1 | FLUORINATED COMPOUNDS | NPS PHARMACEUTICALS, INC. (US) | 2007-07-05 | — | — | WO | claimed |
| US-20140018549-A1 | USE OF D-SERINE DERIVATIVES FOR THE TREATMENT OF ANXIETY DISORDERS | NPS PHARMACEUTICALS, INC. (US) | 2014-01-16 | — | — | US | disclosed |
| US-20140018549-A1 | USE OF D-SERINE DERIVATIVES FOR THE TREATMENT OF ANXIETY DISORDERS | NPS PHARMACEUTICALS, INC. (US) | 2014-01-16 | — | — | US | disclosed |
| US-20140018549-A1 | USE OF D-SERINE DERIVATIVES FOR THE TREATMENT OF ANXIETY DISORDERS | NPS PHARMACEUTICALS, INC. (US) | 2014-01-16 | — | — | US | disclosed |
| US-8450336-B2 | Use of D-serine derivatives for the treatment of anxiety disorders | NPS PHARMACEUTICALS, INC (US) | 2013-05-28 | — | — | US | disclosed |
| US-8450336-B2 | Use of D-serine derivatives for the treatment of anxiety disorders | NPS PHARMACEUTICALS, INC (US) | 2013-05-28 | — | — | US | disclosed |
| US-8450336-B2 | Use of D-serine derivatives for the treatment of anxiety disorders | NPS PHARMACEUTICALS, INC (US) | 2013-05-28 | — | — | US | disclosed |
| US-7902401-B2 | Fluorinated compounds | NPS PHARMACEUTICALS, INC. (US) | 2011-03-08 | — | — | US | disclosed |
| US-20100016403-A1 | USE OF D-SERINE DERIVATIVES FOR THE TREATMENT OF ANXIETY DISORDERS | NPS PHARMACEUTICALS, INC. | 2010-01-21 | — | — | US | disclosed |
| US-20100016403-A1 | USE OF D-SERINE DERIVATIVES FOR THE TREATMENT OF ANXIETY DISORDERS | NPS PHARMACEUTICALS, INC. | 2010-01-21 | — | — | US | disclosed |
| US-20100016403-A1 | USE OF D-SERINE DERIVATIVES FOR THE TREATMENT OF ANXIETY DISORDERS | NPS PHARMACEUTICALS, INC. | 2010-01-21 | — | — | US | disclosed |
| EP-1963277-B1 | FLUORINATED COMPOUNDS | NPS PHARMA INC (US) | 2010-01-20 | — | — | EP | disclosed |
| US-20090005433-A1 | Fluorinated Compounds | NPS PHARMACEUTICALS, INC. | 2009-01-01 | — | — | US | disclosed |
| US-20090005433-A1 | Fluorinated Compounds | NPS PHARMACEUTICALS, INC. | 2009-01-01 | — | — | US | disclosed |
| US-20090005433-A1 | Fluorinated Compounds | NPS PHARMACEUTICALS, INC. | 2009-01-01 | — | — | US | disclosed |
| WO-2007076306-A1 | FLUORINATED COMPOUNDS | NPS PHARMACEUTICALS, INC. (US) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005433-A1 | Fluorinated Compounds | CNR1, NPFFR1, AFF1 | CA1 2396/4885CA2 3413/4885CA12 3096/4885 |
| US-20140018549-A1 | USE OF D-SERINE DERIVATIVES FOR THE TREATMENT OF ANXIETY DISORDERS | OXSR1, SRR, GLRB | CA1 1750/4885CA2 3441/4885CA12 2419/4885 |
| US-20100016403-A1 | USE OF D-SERINE DERIVATIVES FOR THE TREATMENT OF ANXIETY DISORDERS | OXSR1, SRR, GLRB | CA1 1765/4885CA2 3466/4885CA12 2432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.